Article ID Journal Published Year Pages File Type
6184704 Gynecologic Oncology 2016 5 Pages PDF
Abstract
Farletuzumab plus carboplatin/pegylated liposomal doxorubicin in women with platinum-sensitive EOC demonstrated a safety profile consistent with that of carboplatin plus pegylated liposomal doxorubicin.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Preview
Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer
Authors
, , , , , , ,